The session will:

• Share the outcomes of new clinical data for Trevicta, paliperidone palmitate, in adult schizophrenia.
• Discuss common misconceptions and answer questions around the use of LAIs
• Explore how less frequent administrations can enable patient-clinician interactions to focus on holistic aspects of care and to lessen the burden of treating schizophrenia

This promotional symposium is organised and funded by Johnson & Johnson and is intended for UK healthcare professionals only.

Prescribing information is available here: https://www.janssen-pi.co.uk/en/pi-combination/121

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com

Job Code: CP-449356

Date of Preparation: April 2024